Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
WuXi Biologics (Cayman) 14-Day RSI Related Terms
WXIBF vs VRTX, REGN, MRNA: 14-Day RSI Comparison
For the Biotechnology subindustry, WuXi Biologics (Cayman)'s 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi Biologics (Cayman) 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s 14-Day RSI distribution charts can be found below:
* The bar in red indicates where WuXi Biologics (Cayman)'s 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi Biologics (Cayman) (WXIBF) has a 14-Day RSI of 57.94 as of Sep. 22, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on WuXi Biologics (Cayman) and its competitors. According to the industry distribution chart, WuXi Biologics (Cayman) ranks #1253 out of 1416 companies in the Biotechnology industry, placing it in the top 88.5%.
Is WuXi Biologics (Cayman)'s 14-Day RSI too high?
WuXi Biologics (Cayman)'s current 14-Day RSI is 57.94. The Biotechnology industry median 14-Day RSI is 45.78. WuXi Biologics (Cayman)'s value of 57.94 is 26.6% above this industry median. Based on the distribution chart, WuXi Biologics (Cayman) ranks #1253 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, WuXi Biologics (Cayman) has a GF Score™ of 94/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s 14-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, WuXi Biologics (Cayman) ranks #1253 out of 1416 companies for 14-Day RSI. This places WuXi Biologics (Cayman) in the lower half of its industry. The industry median 14-Day RSI is 45.78. WuXi Biologics (Cayman)'s value of 57.94 is 26.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 45.78, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WuXi Biologics (Cayman)'s current 14-Day RSI of 57.94 is 26.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on WuXi Biologics (Cayman) and its competitors. For the Biotechnology industry, the median 14-Day RSI is 45.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WuXi Biologics (Cayman)'s current 14-Day RSI is 57.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) (WXIBF) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.41, compared to a current price of $6.01 — trading 11.1% above its estimated fair value. The current 14-Day RSI is 57.94 and 26.6% above the Biotechnology industry median of 45.78. WuXi Biologics (Cayman)'s overall GF Score™ is 94/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For WuXi Biologics (Cayman) (WXIBF), the current 14-Day RSI is 57.94 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WuXi Biologics (Cayman) (WXIBF) Overvalued in 2026?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be overvalued.
The current stock price of $6.01 is trading 11.1% above its estimated GF Value™ of $5.41.
GuruFocus considers WuXi Biologics (Cayman) to be Modestly Overvalued.
Key valuation signals for WXIBF:
14-Day RSI: 57.94
GF Value™: $5.41 vs. price of $6.01 (11.1% above fair value)
Industry Position: 26.6% above the Biotechnology median (#1253 of 1416)
No single metric tells the full story. See the WXIBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WuXi Biologics (Cayman) Inc. is a global contract research, development, and manufacturing organization (CRDMO) focused on biologics. Incorporated in 2014 as a spin-off from WuXi PharmaTech, it provides end-to-end services spanning drug discovery, cell line development, clinical and commercial manufacturing, and formulation of antibodies, bispecifics, antibody-drug conjugates, and other biologics. The company operates through integrated platforms including WuXiBody and its multiple "biologics foundry" manufacturing facilities across China, Ireland, Germany, and the United States. Its customers are pharmaceutical and biotechnology companies worldwide, ranging from startups to large multinationals. Revenue is generated primarily through fee-for-service contracts tied to project milestones and commercial manufacturing agreements, with a significant portion derived from North American and European clients. WuXi Biologics competes with other large biologics CDMOs such as Lonza, Samsung Biologics, and Fujifilm Diosynth.
94GF Score
Get the complete analysis for WXIBF
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WXIBF has been successfully added to your 
